b320695d.4881.4d6a.b284.847cd248be24
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.360
- OXIDATIVE_PHOSPHORYLATION+0.330
- PEROXISOME+0.180
- DNA_REPAIR+0.160
- MYC_TARGETS_V1+0.160
- FATTY_ACID_METABOLISM+0.150
- ADIPOGENESIS+0.100
- XENOBIOTIC_METABOLISM+0.100
- GLYCOLYSIS+0.070
- E2F_TARGETS+0.040
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.570
- INFLAMMATORY_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- ALLOGRAFT_REJECTION-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- HEDGEHOG_SIGNALING-0.310
- KRAS_SIGNALING_UP-0.310
- PANCREAS_BETA_CELLS-0.310
- HYPOXIA-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031078_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.862 |
| 2 | 877f3bcc-97ea-4b0e-9f61-98a9eaedd952 | — | — | 0.847 |
| 3 | SRR8943016 | — | — | 0.845 |
| 4 | BS_3F4FQJMR | Supratentorial Ependymoma | — | 0.841 |
| 5 | BS_SDCNP7MW | Ependymoma NOS | — | 0.841 |
| 6 | C3N-03073 | — | cohortA1 | 0.839 |
| 7 | SRR33346942 | — | — | 0.838 |
| 8 | df4e44f9-ee22-43d3-911e-fd4bd826ec0c | — | — | 0.837 |
| 9 | MNG37 | — | — | 0.824 |
| 10 | SRR5088889 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.010 | Inavolisib | — uncovered |